Chapters

Transcript

Video

Can you go into the specific end points for androstenedione, as well as your criteria for allowing progressive down-titration of glucocorticoid in phase 2 of the CAHtalyst trial?

Can you go into the specific end points for androstenedione, as well as your criteria for allowing progressive down-titration of glucocorticoid in phase 2 of the CAHtalyst trial?


Created by

CMEducation Resources | iQ&A Congenital Adrenal Hyperplasia (CAH) Medical Intelligence Zone 

Presenter

Richard Auchus, MD, PhD

Richard Auchus, MD, PhD

Professor of Pharmacology and Internal Medicine
Division of Metabolism, Endocrinology, and Diabetes
University of Michigan School of Medicine
Ann Arbor, Michigan